Serum alkaline phosphatase negatively affects endothelium-dependent vasodilation in naïve hypertensive patients

Francesco Perticone1, Maria Perticone, Raffaele Maio

  • 1Department of Medical and Surgical Sciences, Campus Universitario di Germaneto, V.le Europa, 88100 Catanzaro, Italy. erticone@unicz.it

Insights

High alkaline phosphatase levels are linked to poor endothelial function in hypertensive patients. This association is independent of traditional risk factors and is worsened by elevated serum phosphorus levels.

Area of Science:

  • Cardiovascular Medicine
  • Biochemistry
  • Nephrology

Background:

  • Tissue nonspecific alkaline phosphatase (TNAP) is implicated in arterial calcification and predicts mortality.
  • Endothelial dysfunction is a key factor in cardiovascular disease development.

Purpose of the Study:

  • To investigate the correlation between serum alkaline phosphatase levels and endothelial function in hypertensive patients.
  • To assess the influence of serum phosphorus on this relationship.

Main Methods:

  • 500 treatment-naïve hypertensive patients were divided into tertiles based on serum alkaline phosphatase levels.
  • Endothelial function was assessed using strain gauge plethysmography measuring the response to acetylcholine.
  • Multiple logistic regression analysis and interaction analysis were performed.

Main Results:

  • Serum alkaline phosphatase showed a significant inverse relationship with endothelium-dependent vasodilation (r=−0.55, P<0.001).
  • This association remained significant after adjusting for multiple risk factors (r=−0.61, P<0.001).
  • Patients in the highest tertile of alkaline phosphatase had a 3-fold higher risk of endothelial dysfunction. Elevated serum phosphorus attenuated the relationship between alkaline phosphatase and vasodilation.

Conclusions:

  • Serum alkaline phosphatase is a significant independent predictor of endothelial dysfunction in hypertension.
  • Higher serum phosphorus levels interact with alkaline phosphatase, potentially exacerbating endothelial impairment.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
564
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
741
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.5K
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
723
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
4.8K